Copyright
©2013 Baishideng Publishing Group Co.
World J Gastroenterol. Aug 28, 2013; 19(32): 5334-5339
Published online Aug 28, 2013. doi: 10.3748/wjg.v19.i32.5334
Published online Aug 28, 2013. doi: 10.3748/wjg.v19.i32.5334
Table 1 Prevalence of dysmetabolic diseases and biochemical abnormalities in the total study population n (%)
Patients examined | Positive patients | |
Hyperlipidemia | 2715 | 1035 (38.1) |
Fatty liver | 2605 | 677 (26.0) |
Increased ALT and/or AST levels | 3393 | 405 (11.9) |
Gallstone | 2605 | 296 (11.4) |
HBsAg | 2244 | 198 (8.8) |
Hyperglycemia | 2767 | 203 (7.3) |
Hypertension | 2938 | 210 (7.3) |
Hyperuricemia | 2700 | 167 (6.2) |
Increased Scr levels | 2150 | 10 (6.2) |
Table 2 Age and sex distribution of overall fatty liver prevalence
Age (yr) | All patients | Patients with fatty liver | Overall prevalence | Prevalence in males | Prevalence in females | χ2 | P value |
18-19 | 17 | 1 | 5.80% | 7.10% | 0.00% | - | - |
20-29 | 1055 | 55 | 5.20% | 6.40% | 2.30% | 7.47 | 0.006 |
30-39 | 1003 | 206 | 20.50% | 26.70% | 8.70% | 44.80 | < 0.001 |
40-49 | 799 | 212 | 26.50% | 34.50% | 16.80% | 31.78 | < 0.001 |
50-59 | 331 | 123 | 37.20% | 35.90% | 39.00% | 0.32 | 0.569 |
60-69 | 147 | 58 | 39.50% | 37.80% | 42.10% | 0.27 | 0.601 |
≥ 70 | 81 | 22 | 27.10% | 24.50% | 32.10% | 0.54 | 0.464 |
Total | 2605 | 677 | 26.00% | 32.50% | 15.30% | 95.18 | < 0.001 |
Table 3 Prevalence of dysmetabolic diseases and biochemical abnormalities in the 677 patients diagnosed with fatty liver n (%)
Patients examined | Positive patients | |
Increased ALT and/or AST levels | 676 | 199 (29.4) |
Hypertriglyceridemia | 635 | 197 (31.0) |
Mixed type hyperlipidemia | 635 | 135 (21.3) |
Hypercholesterolemia | 635 | 92 (14.5) |
Hyperglycemia | 640 | 116 (18.1) |
Hypertension | 636 | 102 (16.0) |
Gallstone | 677 | 97 (14.4) |
Hyperuricemia | 627 | 87 (13.9) |
HBsAg | 506 | 39 (7.7) |
Increased Scr levels | 507 | 3 (0.6) |
Table 4 Sex distribution of prevalence of dysmetabolic diseases and biochemical abnormalities in the 430 subjects with fatty liver n (%)
All patients | Male patients | Female patients | χ2 | P value | |
Increased ALT and/or AST levels | 129 (30.0) | 113 (32.6) | 16 (19.3) | 5.63 | 0.018 |
Hypertriglyceridemia | 135 (31.4) | 125 (36.0) | 10 (12.0) | 17.87 | < 0.001 |
Mixed type hyperlipidemia | 90 (20.9) | 65 (18.7) | 25 (30.1) | 5.25 | 0.022 |
Hypercholesterolemia | 53 (12.3) | 33 (9.5) | 20 (24.1) | 13.19 | < 0.001 |
Hyperglycemia | 76 (17.6) | 59 (17.0) | 17 (20.5) | 0.56 | 0.455 |
Hypertension | 69 (16.0) | 53 (15.3) | 16 (19.3) | 0.80 | 0.372 |
Hyperuricemia | 66 (15.3) | 60 (17.3) | 6 (7.2) | 5.22 | 0.022 |
Gallstone | 62 (14.4) | 50 (14.4) | 12 (14.4) | 0.00 | 0.991 |
HBsAg | 34 (7.9) | 27 (7.9) | 7 (7.9) | 0.04 | 0.843 |
Increased Scr levels | 3 (0.7) | 3 (0.9) | 0 (0.0) | - | - |
Table 5 Distribution of prevalence of risk factors in patients with and without fatty liver
Patients with fatty liver (n = 430) | Patients without fatty liver (n = 495) | χ2 | P value | |||
All patients | Prevalence | All patients | Prevalence | |||
Hypertriglyceridemia | 135 | 31.40% | 45 | 9.10% | 73.04 | < 0.001 |
Mixed type hyperlipidemia | 90 | 20.90% | 33 | 6.70% | 40.61 | < 0.001 |
Hypercholesterolemia | 53 | 12.30% | 95 | 19.20% | 8.07 | 0.004 |
Hyperglycemia | 76 | 17.70% | 25 | 5.00% | 37.70 | < 0.001 |
Hypertension | 69 | 16.00% | 32 | 6.50% | 21.72 | < 0.001 |
Hyperuricemia | 66 | 15.30% | 14 | 2.80% | 45.66 | < 0.001 |
- Citation: Liao XH, Cao X, Liu J, Xie XH, Sun YH, Zhong BH. Prevalence and features of fatty liver detected by physical examination in Guangzhou. World J Gastroenterol 2013; 19(32): 5334-5339
- URL: https://www.wjgnet.com/1007-9327/full/v19/i32/5334.htm
- DOI: https://dx.doi.org/10.3748/wjg.v19.i32.5334